Kurt Hilpert

Design and Synthesis of Potent and Highly Selective Thrombin Inhibitors

Kurt Hilpert, Jean Ackermann, David W. Banner et al. · Journal of Medicinal Chemistry · 1994 · 189 citations · Full text

4-((<i>R</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y₁₂ Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel

Eva Caroff, Francis Hubler, Emmanuel A. Meyer et al. · Journal of Medicinal Chemistry · 2015 · 50 citations

Disease-relevant Platelet Aggregation, Pharmacotherapy, Experimental Pharmacology +20

Discovery and Optimization of 4,5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase and Heat Shock Protein 90

Tao Meng, Dadong Zhang, Zuoquan Xie et al. · Journal of Medicinal Chemistry · 2014 · 44 citations · Full text

Potent Dual Inhibitors, Combinatorial Chemistry, Medicinal Chemistry +14

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma

Alain Gast, T. Tschopp, Georg H. Schmid et al. · Blood Coagulation & Fibrinolysis · 1994 · 43 citations

Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist

Heinz Fretz, Anja Valdenaire, Julien Pothier et al. · Journal of Medicinal Chemistry · 2013 · 41 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Chemical Biology +20